系统生物医学 教授
职称：教授
学科专业：系统生物医学
研究方向：治疗相关毒副作用，肿瘤免疫治疗，细胞衰老。
行政职务：无
电子邮箱：yjing@jnu.edu.cn
个人简介：理学博士，教授，博士生导师。先后入选广东省珠江人才计划、广州市重大人才工程、上海市海外高层次人才、上海市浦江人才计划等多个省市级人才项目。在美国德克萨斯大学休斯顿健康科学中心完成博士后研究，曾任上海交通大学医学院副研究员、粤港澳大湾区精准医学研究院（广州）青年研究员。主要研究方向为抗肿瘤疗法的疗效与毒副作用机制解析，聚焦免疫相关不良事件（irAEs）的发生发展过程，并构建可应用于临床实践的人工智能预测模型。在Nat Rev Clin Oncol.（2篇）、Cancer Cell、Gut、Adv Sci.（2篇）、Nat Comm.(2篇)等国际顶级期刊发表系列高水平学术成果，其中irAEs相关研究成果被美国临床肿瘤学会（ASCO）临床管理指南引用；累计授权/申请发明专利3项，作为主要参与人完成的肺部肿瘤早期精准诊疗关键策略与应用项目获2023年北京医学科技奖二等奖。
2009.09—2014.07 复旦大学，生物化学与分子生物学，博士；
2005.09—2009.07 西南大学，生物科学类，学士。
2026.05—至今 暨南大学, 基础医学与公共卫生学院，教授；
2023.03—2026.04 粤港澳大湾区精准医学研究院（广州）, 青年研究员；
2021.01—2023.03 上海交通大学医学院, 副研究员；
2018.07—2020.08 美国得州州立大学(UTHealth)， 博士后；
2014.10—2018.06 仁济医院, 助理研究员。
1. Lei Zhang*, Xiaokai Fan, Jun Ma*, Jun Zhang*, Ying Wei, Bin Hu, Di Zhou, Junjun Zhou, Yongrui Bai, Xiumei Ma, Jian Song#, Jianming Tang#, Haiyan Chen#, Ying Jing#. Distinct immune cell dynamics associated with immune-related adverse events during combined chemoradiation and immune checkpoint inhibitor therapy. Nature Communications, 2025, 16(1): 11565.
2. Lei Zhang*, Jun Ma*, Jun Zhang, Minjie Hu, Jinlin Cheng, Bin Hu, Junjun Zhou, Di Zhou, Yongrui Bai, Xiumei Ma#, Jianming Tang#, Haiyan Chen#, Ying Jing#. Radiotherapy-Associated Cellular Senescence and EMT Alterations Contribute to Distinct Disease Relapse Patterns in Locally Advanced Cervical Cancer. Advanced Science, 2025, 12(12): e2412574.
3. Lei Zhang*, Jun Ma*, Di Zhou, Junjun Zhou, Bin Hu, Xiumei Ma, Jianming Tang#, Yongrui Bai#, Haiyan Chen#, Ying Jing#. Single-Nucleus Transcriptome Profiling of Locally Advanced Cervical Squamous Cell Cancer Identifies Neural-Like Progenitor Program Associated with the Efficacy of Radiotherapy. Advanced Science, 2023, 10(25): e2300348.
4. Minjiang Chen*, Pengfei Ma*, Yongchang Zhang*, Dong Wang*, Zhuang Yu, Yujie Fu, Xiaojing Zhao, Mengzhao Wang#, Guanglei Zhuang#, Ying Jing#. Divergent tumor and immune cell reprogramming underlying immunotherapy response and immune-related adverse events in lung squamous cell carcinoma. Journal for Immunotherapy of Cancer, 2023, 11(10): e007305.
5. Ying Jing#*, Yuan Liu*, Qiang Li, Youqiong Ye, Lixia Diao, Yun Huang, Yubin Zhou, Michael R. Green, Gorden B. Mills, Leng Han#. Expression of chimeric antigen receptor therapy targets detected by single-cell sequencing of normal cells may contribute to off-tumor toxicity. Cancer Cell, 2021, 39(12): 1558-1559.
6. Ying Jing*, Jingwen Yang*, Douglas B Johnson#, Javid J Moslehi#, Leng Han#. Harnessing big data to characterize immune-related adverse events. Nature Reviews Clinical Oncology, 2022, 19(4): 269-280.
7. Xiaoqi Yu, Qiming Gong, Demin Yu, Yongyan Chen, Ying Jing#, Fabien Zoulim#, Xinxin Zhang#. Spatial transcriptomics reveals a low extent of transcriptionally active hepatitis B virus integration in patients with HBsAg loss. Gut, 2024, 73(5): 797-809.
8. Xuwen Lin, Xidong Ma, Sheng Zhao, Jie Yao, Leng Han#, Ying Jing#, Xinying Xue#. Cardiovascular Toxicity in Anti-Tumor Therapy: Biological and Therapeutic Insights. Trends in Cancer, 2024, 10(10): 920-934.
9. Xuwen Lin, Mei Xie, Jie Yao, Xidong Ma, Lin Qin, Xu-Mei Zhang, Jialin Song, Xinyu Bao, Xin Zhang, Yinguang Zhang, Yiming Liu, Wenya Han, Yiran Liang, Ying Jing#, Xinying Xue#. Immune-related adverse events in non-small cell lung cancer: Occurrence, mechanisms and therapeutic strategies. Clinical and Translational Medicine, 2024, 14(3): e1613.
10. Jingwen Yang*, Yamei Chen*, Ying Jing*, Michael R. Green#, Leng Han#. Advancing CAR T-cell therapy through multi-dimensional omics data. Nature Reviews Clinical Oncology, 2023, 20(4): 211-228.
11. Ying Jing*, Xue Chen*, Kunyan Li, Yaoming Liu, Zhao Zhang, Yiqing Chen, Yuan Liu, Yushu Wang, Steven H Lin, Lixia Diao, Jing Wang, Yanyan Lou, Douglas B Johnson, Xiang Chen#, Hong Liu#, Leng Han#. Association of antibiotic treatment with immune-related adverse events in patients with cancer receiving immunotherapy. Journal for Immunotherapy of Cancer, 2022, 10(1): e003779.
12. Ying Jing*, Jin Liu*, Youqiong Ye, Lei Pan, Hui Deng, Yushu Wang, Yang Yang, Lixia Diao, Steven H. Lin, Gordon B. Mills, Guanglei Zhuang#, Xinying Xue#, Leng Han#. Multi-omics prediction of immune-related adverse events during checkpoint immunotherapy. Nature Communications, 2020, 11(1): 4946.
13. Ying Jing*, Yongchang Zhang*, Youqiong Ye, Yaoming Liu, Yanyan Lou, Steven H. Lin, Lixia Diao, Hong Liu, Gordon B. Mills#, Leng Han#. Association between sex and immune-related adverse events during immune checkpoint inhibitor therapy. Journal of the National Cancer Institute, 2021, 113(10): 1396-1404.
14. Ying Jing#, Lixia Diao#, Leng Han#. Adverse events associated with potential drugs for COVID-19: a case study from real-world data. Briefings in Bioinformatics, 2021, 22(2): 1232-1238.
*共同第一作者，#共同通讯作者
2023年获北京医学科技奖二等奖。
1.人工智能与生命科学专委会专委；
2.中欧设备学会呼吸与危重症专委会专委；
3.Military Medical Research 青年编委。
